Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × Axitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 49 Kidney Neoplasms 14 Neoplasms 12 Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 8 Melanoma 7 Colorectal Neoplasms 7 Carcinoma, Hepatocellular 7 Glioblastoma 5 Carcinoma 5 Lung Neoplasms 4 Uterine Cervical Neoplasms 3 Recurrence 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Thyroid Neoplasms 2 Stomach Neoplasms 2 Skin Neoplasms 2 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Liver Neoplasms 2 Kidney Diseases 2 Advanced Solid Tumors 2 cT2a N0NxM0 Renal Tumor 1 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uveal Melanoma 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1

Interventions

Pemetrexed 11 Carboplatin 11 osimertinib 10 aflutinib 8 Drug Therapy 8 Gefitinib 7 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 tislelizumab 3 pembrolizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2 HMPL-013 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡